Skip to content

Not medical advice. Talk to your provider before using any peptide. Full disclaimer

BAM-15 iconBAM-15Small moleculeNo amino acid sequence. Icon reflects category theme only.

BAM-15

Beginner tier: 200 mg, daily · preclinical extrapolation

MetabolicResearch
1.7 h half-life·Oral

Also known as: BAM15, BAM 15

Mice on a high-fat western diet lost body fat without eating less, exercising more, or losing lean mass. BAM-15 (CAS 210302-17-3) is the mitochondrial uncoupler behind that result, a small molecule that forces cells to burn extra fuel by short-circuiting the proton gradient in mitochondria. No human clinical trials exist yet, and all dosing comes from allometric scaling of rodent studies. Bodybuilders and metabolic optimization communities discuss it as a mechanistically cleaner alternative to DNP, with the critical caveat that community doses sit 5 to 30 times below the estimated therapeutic range.

What Is BAM-15?

BAM-15 (N5,N6-bis(2-fluorophenyl)-[1,2,5]oxadiazolo[3,4-b]pyrazine-5,6-diamine, CAS 210302-17-3) is a small-molecule mitochondrial protonophore, not a peptide. It shows up in peptide communities because the target audience overlaps. Mice on a western diet lost body fat, improved insulin sensitivity, and showed lower hepatic lipid levels after five weeks of BAM-15, started after four weeks on the diet (Alexopoulos et al.)[1]. Lean mass, body temperature, and food intake all stayed the same.

BAM-15 is a selective uncoupler. The molecule dissipates the proton motive force across the inner mitochondrial membrane. Cells respond by oxidizing more glucose and fatty acids to restore their electrochemical gradient, burning additional calories in the process. The key selling point over older uncouplers like DNP: BAM-15 depolarizes mitochondria without touching the plasma membrane. That selectivity means lower cytotoxicity at working concentrations (Kenwood et al., Mol Metab 2014)[2].

Real-world use has no FDA-approved product behind it, and BAM-15 appears in none of FDA's 503A or 503B nomination categories. Community protocols run 50 to 300 mg per day split across two or three oral doses. Allometric scaling from mouse data puts the estimated therapeutic range at 500 to 1,500 mg per day. That gap has never been bridged by a human trial. Oral bioavailability lands around 67% in mice with a 1.7-hour half-life, meaning plasma levels drop to near zero within four hours of each dose.

Research status: preclinical only. WADA added BAM-15 to the prohibited list under S4.4.1 effective January 1, 2026. The compound holds an "emerging-research" classification with a safety grade of C.

How BAM-15 Works

The electron transport chain pumps protons from the mitochondrial matrix into the intermembrane space, building a proton motive force that drives ATP synthase. BAM-15 bypasses ATP synthase entirely. It carries protons back across the inner mitochondrial membrane through a non-enzymatic pathway, collapsing the electrochemical gradient.

The aniline nitrogen on the oxadiazolopyrazine scaffold handles proton shuttling. On planar bilayer lipid membranes and in liposomes, BAM-15 drives proton conductance at potency comparable to the classical uncoupler CCCP (Antonenko et al.)[3]. In isolated rat liver mitochondria, it collapses membrane potential, accelerates respiration rate, and triggers calcium efflux.

Selectivity matters here. DNP and FCCP depolarize both the inner mitochondrial membrane and the plasma membrane. BAM-15 only depolarizes mitochondria. Cells ramp up oxygen consumption and substrate oxidation to compensate for the lost gradient, burning extra glucose and fatty acids, but the plasma membrane stays intact. That distinction explains the lower cytotoxicity profile. In cell-based assays, BAM-15 can sustain maximal mitochondrial respiration without triggering apoptosis. DNP cannot do that safely.

The downstream metabolic result: increased whole-body energy expenditure and fat oxidation without sympathomimetic stimulation. No catecholamine release. No CNS activation. No heart rate increase. The calorie burn happens at the mitochondrial level, which is why body temperature stayed normal even at supratherapeutic mouse doses.

BAM-15 Benefits

  • BAM-15 benefits center on fat loss and metabolic improvement through mitochondrial uncoupling.
  • Fat mass reduction without caloric restriction or appetite suppression; mice on a high-fat diet lost body fat while eating the same amount of food (five weeks of BAM-15 in diet-fed C57BL/6J mice)[1].
  • Whole-body insulin sensitivity improvement in mice, confirmed by the gold-standard hyperinsulinemic-euglycemic clamp (Alexopoulos et al., Nature Communications 2020).
  • Hepatic lipid accumulation decreased in treated mice. This has potential relevance to metabolic dysfunction-associated steatotic liver disease, though no human liver imaging data exists.
  • Oral bioavailability of approximately 67% in mice. No needles. Take it as a capsule with food.
  • Safety profile in preclinical data separates BAM-15 from DNP: no hyperthermia at any tested mouse dose, including 200 mg/kg (Alexopoulos et al.)[1]; no plasma membrane depolarization (Kenwood et al.)[2]; no apoptosis at effective concentrations.
  • Rapid clearance within four hours limits accumulation risk. DNP has a 36-hour half-life, which is why overdose becomes fatal; BAM-15 clears before toxicity could compound across doses.

BAM-15: Science vs Community Consensus

Divergent
Scientific Evidence
Weak
Based on 9 key studies·Research only

Reduces body fat mass, improves whole-body insulin sensitivity, and increases energy expenditure in mouse models without hyperthermia or lean mass loss at any tested dose.

Dosing studied: ~500–1,500 mg/day (allometric scaling from 0.05–0.15% dietary w/w in mice); no validated human dose established
Read the evidence (key study, limitations)

No human trials exist.

Key Study

Alexopoulos et al. Nature Communications 2020 (PMID 32409697): western-diet C57BL/6J mouse study (5 weeks of BAM-15 after 4 weeks on the diet) with hyperinsulinemic-euglycemic clamp confirmation; primary efficacy reference

Limitations

All efficacy and safety data from rodent studies only; 1.7-hour half-life limits sustained exposure; gram-scale allometric doses untested in humans; no Phase 1 safety trial; WADA-prohibited as of January 1, 2026; no human PK data

Community Experience
Weak
3.5/5
Based on very small: niche research community

Experimental metabolic agent positioned as mechanistically safer DNP alternative.

Community dosing: 50–300 mg/day split 2–3x daily (derived from commercial capsule sizing of 15–50 mg/cap; not validated)
Read the reports (what users report 4, common issues 6)

Cautiously interested community; no structured n-of-1 outcome data with biomarker confirmation.

What users report (4)
  • No stimulant feel or elevated heart rate (mechanism distinguishes it from ephedrine/clenbuterol)
  • No hyperthermia in preclinical data even at 200 mg/kg mouse dose (distinguishes from DNP)
  • Oral administration: no injections required
  • Rapid clearance within ~4 hours limits accumulation risk relative to DNP (36-hour half-life)
Common issues (6)
  • No human outcome data: no confirmed self-experimenter biomarker reports in literature
  • Community doses (50–300 mg/day) are 5–30x below allometric estimates (500–1,500 mg/day)
  • Short 1.7-hour half-life makes once-daily dosing near-ineffective for sustained metabolic effect
  • WADA-prohibited effective January 1, 2026 (S4.4.1): athletes face sanctions
  • Reported as adulterant in some dietary supplements: quality control not guaranteed
  • Gram-scale dosing required for allometric equivalence is practically impractical and costly
Science & Community Diverge

Science establishes mechanism and mouse-level dose range (~500–1,500 mg/day allometric); community uses 50–300 mg/day based on commercial capsule sizing with no efficacy validation. Two-orders-of-magnitude gap is unresolved. No human trial bridges them. Community use may reflect sub-therapeutic dosing or a conservative safety stance given complete absence of human data.

BAM-15 Dosage Guide

ExtrapolatedDose extrapolated from mouse metabolic studies using allometric scaling; no human data
LevelDoseFrequency
Beginner200 mgDaily
Moderate400 mgDaily
Aggressive600 mgDaily
Note:

BAM-15 is an oral small molecule. No reconstitution, no bacteriostatic water, no syringes. It comes as powder or pre-made capsules.

The short half-life (1.7 hours) means once-daily dosing is near-pointless. You need at least two doses per day spaced six hours apart. Three is better if you can manage it. Morning, early afternoon, and late afternoon with food works for most schedules. Skip the evening dose if it affects sleep.

Powder quality matters here. Lab-reagent BAM-15, sold only for research, comes HPLC-verified with proper CAS verification (210302-17-3). Gray-market capsules don't carry the same quality accountability; dosing accuracy in DIY capsules is suspect because BAM-15 has low water solubility, making even powder distribution inside gelatin caps inconsistent.

Store powder at negative 20 degrees Celsius, desiccated, away from light. If you dissolve it in DMSO for research use, that solution stays stable at negative 20 degrees Celsius for up to six months. Avoid repeated freeze-thaw cycles.

The community dose range (50 to 300 mg per day) sits 5 to 30 times below what allometric scaling predicts as therapeutic. That might mean sub-therapeutic dosing or conservative safety reasoning. Nobody knows yet.

Cycling Protocol

On Period
8 weeks
Off Period
4 weeks

No established human cycling protocol exists. In the primary mouse study, BAM-15 was administered continuously via diet for the study duration. An 8-week-on, 4-week-off schedule is a conservative extrapolation commonly discussed in research communities. The short half-life means pharmacological effects cease within hours of the last dose, so extended washout periods are likely unnecessary from a pharmacokinetic standpoint. Cycling rationale is based on general precaution rather than observed tolerance or tachyphylaxis.

Calculate your BAM-15 dose
Dosing tiers, timing, and cycle length

Or use the universal Peptide Calculator for any peptide.

BAM-15 Protocols by Goal

advancedCommunity8 weeks on, 4 weeks off (precautionary; not pharmacokinetically driven)
Titration phase
Wk 1–2
50 mg · 2x daily (AM + midday) with food · Oral
Maintenance phase
Wk 3–8
100–200 mg · 2–3x daily with food · Oral

Expected: Unknown in humans. Mouse model: significant fat mass reduction and insulin sensitivity improvement detectable at weeks 3–6 at 0.10% dietary doses. Human outcome at community doses (sub-allometric) is unvalidated: benefits may be absent or unmeasurable.

Monitor: Liver function panel (ALT, AST, ALP) at baseline and 4 weeks: BAM-15 primarily accumulates in liver. Fasting glucose and insulin at baseline and end of cycle. Body temperature spot-checks if any warmth sensation occurs.

How to Use BAM-15

  1. 1
    Step 1

    Start with BAM-15 powder backed by a certificate of analysis showing HPLC purity of 98% or above. Verify the CAS number (210302-17-3) matches.

  2. 2
    Step 2

    If using bulk powder, weigh individual doses on a milligram scale (0.001 g precision minimum). For a 50 mg starting dose, that is 0.050 g. Transfer into size 4 gelatin capsules, or dissolve in a lipophilic carrier if preferred.

  3. 3
    Take the first dose in the morning with food

    Food reduces potential GI discomfort and may improve absorption given the compound's low water solubility.

  4. 4
    Step 4

    Take the second dose approximately six hours later, also with food. This timing strategy maintains detectable plasma levels across roughly 8 of 16 waking hours; the 1.7-hour half-life makes single daily dosing ineffective for sustained exposure.

  5. 5
    Optional third dose in the late afternoon, again with food

    Avoid evening dosing if you notice any sleep disruption.

  6. 6
    Step 6

    Start at 50 mg per dose (100 mg per day total) for weeks one and two. If tolerated, increase to 100 to 200 mg per dose during weeks three through eight, for a total daily intake of 200 to 600 mg.

  7. 7
    Step 7

    Monitor body temperature daily for the first two weeks (oral thermometer). Any reading above 38.0 degrees Celsius (100.4 degrees Fahrenheit) that correlates with dosing is an absolute stop signal.

  8. 8
    Step 8

    Run a liver function panel (ALT, AST, ALP) at baseline, week four, and the end of the eight-week cycle. Stop if transaminases exceed 1.5 times the upper limit of normal.

Alternative Routes

Oral (capsule or dissolved in lipophilic carrier)

Oral bioavailability ~67% in mice; no human PO bioavailability data

All mouse efficacy studies used dietary administration. BAM-15 has low water solubility: formulation in lipophilic carrier or encapsulation improves absorption. Standard capsule form is the community route.

DMSO solution (intraperitoneal: animal research only)

IP administration bypasses first-pass metabolism; not valid for human extrapolation

Some mouse mechanistic studies used IP injection. Do not extrapolate IP mouse doses to oral human protocols.

BAM-15 Stacking Protocols

Works With

Avoid

DNP (2,4-dinitrophenol)

Additive mitochondrial uncoupling: both compounds dissipate the proton gradient. Combined use creates dangerous risk of excessive energy depletion and potentially fatal hyperthermia.

Do not combine
FCCP / CCCP (uncoupling research chemicals)

Direct pharmacodynamic overlap: additive uncoupling of inner mitochondrial membrane. No therapeutic window at combined doses.

Do not combine
Metformin

Metformin inhibits Complex I while BAM-15 dissipates the proton gradient: theoretical risk of excessive mitochondrial stress and lactic acidosis. Not studied.

Thyroid hormones (levothyroxine, T3)

Thyroid hormones naturally increase metabolic rate via mitochondrial mechanisms. Additive thermogenic and energy expenditure effect is plausible; could cause excessive energy depletion.

Estimated Cost

BAM-15 Side Effects

No human has ever taken BAM-15 in a controlled clinical setting. Every safety claim about this compound traces back to cell culture dishes and mice. That context matters more than any individual finding.

In preclinical experiments, mice receiving BAM-15 intraperitoneally for over seven days showed no obvious clinical toxicity at any tested dose. Hematological and biochemical markers stayed within normal ranges [1]. Body temperature remained unchanged, which is a meaningful signal because the defining danger of classical uncouplers like DNP is fatal hyperthermia. BAM-15 did not trigger apoptosis at effective concentrations in cell-based assays. At very high concentrations, slight inhibition of mitochondrial respiration was observed, but substantially less than what FCCP produces at comparable levels.

The short 1.7-hour half-life cuts both ways. If something goes wrong, the compound clears within hours. But it also means any adverse effect from a single dose would be transient, making chronic toxicity harder to detect without long-term studies that haven't been done.

Theoretical risks based on mechanism: excessive energy depletion with overdose. Mitochondrial uncoupling forces cells to burn more fuel. Push that too hard and energy-demanding tissues (heart, brain, liver) could become fuel-starved. This has not been observed in published BAM-15 studies, but it is the established lethality mechanism of DNP.

Liver accumulation deserves attention. BAM-15 concentrates in hepatic tissue based on mouse pharmacokinetics. Liver function monitoring (ALT, AST) at baseline, mid-cycle, and end of cycle is the minimum standard. Stop immediately if transaminases exceed two times the upper limit of normal.

Pregnancy and breastfeeding: no reproductive safety data exists. Avoid completely. Individuals with known mitochondrial disorders (mitochondrial myopathy, MELAS) should not use BAM-15 because uncoupling can worsen the energy deficit those conditions already produce.

WADA added BAM-15 to the prohibited substance list under S4.4.1 effective January 1, 2026. Any athlete or military personnel subject to testing faces sanctions.

Quality control is a genuine concern. BAM-15 has been found as an undeclared adulterant in dietary supplements. The reverse (labeled BAM-15 containing a different compound) is also a documented quality risk. Only a certificate of analysis with HPLC purity of 98% or above confirms what a batch contains.

Common Issues & Solutions

Dosing timing: Once-daily dosing is near-ineffective given the 1.7-hour half-life. Minimum of 2x daily split dosing (AM + early afternoon) is required for any sustained plasma exposure.

No stimulant effect expected: Unlike DNP in its initial phase or ephedrine, BAM-15 is not sympathomimetic. Absence of warmth or energy surge does not indicate product failure.

Gram-scale gap: Community doses (50–300 mg/day) are sub-allometric by 5–30x. If no measurable effect at 300 mg/day split 3x, the literature would suggest scaling toward 500+ mg: but there is no human safety data at these doses.

Product authenticity: BAM-15 has been found as an undeclared adulterant in dietary supplements and the reverse (labeled BAM-15 that is a different compound) is also a quality risk. A COA with HPLC purity ≥98% is the minimum standard.

WADA status: As of January 1, 2026, BAM-15 is prohibited under S4.4.1 (Metabolic Modulators). Any athlete or military personnel subject to anti-doping testing must not use this compound.

Ask AI about this page

Ask AI for a second opinion on BAM-15 dosing and side effects

Contraindications

  • Pregnancy or breastfeeding: no reproductive safety data available
  • Known mitochondrial disorders (e.g., mitochondrial myopathy, MELAS): uncoupling may worsen energy deficit
  • Severe hepatic impairment: BAM-15 primarily accumulates in the liver
  • History of hyperthermia or malignant hyperthermia susceptibility
  • Active use of other mitochondrial uncouplers (DNP, FCCP): additive uncoupling risk
  • Caloric restriction below 1,200 kcal/day: increased energy expenditure may cause excessive energy deficit
  • Children and adolescents: no safety data in developing organisms

Drug Interactions

  • DNP and other mitochondrial uncouplers: additive uncoupling effect could cause dangerous energy depletion and hyperthermia
  • Metformin: both compounds affect mitochondrial function; metformin inhibits Complex I while BAM-15 dissipates proton gradient; theoretical risk of excessive mitochondrial stress
  • Insulin and sulfonylureas: BAM-15 improves insulin sensitivity, which could potentiate hypoglycemic effects
  • Thyroid hormones (levothyroxine): thyroid hormones naturally increase metabolic rate; additive thermogenic effect possible
  • Beta-2 agonists (clenbuterol, albuterol): combined metabolic stimulation may cause excessive energy expenditure
  • Statins: some statins have mitochondrial effects; theoretical interaction with concurrent uncoupling, though not studied

Product Quality

Recommended Monitoring

TestWhenTarget
Liver function panel (ALT, AST, ALP, bilirubin)Baseline, week 4 (mid-cycle), end of 8-week cycleALT/AST within 1.5x ULN; stop immediately if >2x ULN
Fasting glucose and insulin (HOMA-IR)Baseline and end of cycleFasting glucose <100 mg/dL; HOMA-IR <2.0 as general metabolic health marker
Body temperature (oral or axillary)Daily for first 2 weeks; weekly thereafterNormal: 36.1–37.2°C (97–99°F). Stop if >38.0°C (100.4°F) with BAM-15 as likely cause.
Basic metabolic panel (electrolytes, creatinine, BUN)Baseline and end of cycleNot listed
Liver function panel (ALT, AST, ALP, bilirubin)

BAM-15 primarily accumulates in the liver in mouse pharmacokinetics (Cmax hepatic). Hepatic safety signal is the most likely first indicator of any human toxicity.

Fasting glucose and insulin (HOMA-IR)

Primary efficacy endpoint in mouse studies; also monitors for hypoglycemia risk if stacking with insulin sensitizers.

Body temperature (oral or axillary)

Hyperthermia is the defining safety concern for mitochondrial uncouplers (fatal with DNP). No temperature elevation observed in mice even at supratherapeutic doses; monitoring confirms this translates to human use.

Basic metabolic panel (electrolytes, creatinine, BUN)

BAM-15 showed protective effects in sepsis-associated kidney injury in mice (PMID 36757801) but human renal effects are unknown. Electrolyte status relevant given increased mitochondrial substrate oxidation.

BAM-15 Before and After

Days 1-3

Initial dosing phase. Due to the short 1.7-hour half-life, plasma levels do not accumulate significantly between doses. Some users report a subtle increase in warmth or metabolic rate within hours of dosing. No visible body composition changes expected.

Weeks 1-2

Consistent daily dosing establishes a pattern of transient mitochondrial uncoupling. Increased energy expenditure may become noticeable during active dosing windows. No measurable fat loss expected yet in most individuals.

Weeks 3-6

Based on mouse model data, fat mass reduction becomes measurable with sustained daily administration. Insulin sensitivity improvements were detectable by this timeframe in preclinical studies. Hepatic lipid levels may begin to decrease.

Weeks 7-8

In the mouse obesity study, significant reductions in body fat mass and improved glycemic control were well established by this point. Body temperature and lean mass remained unchanged throughout. Effects are expected to reverse within days of discontinuation given the short half-life.

What to Expect

Days 1 through 7: Titration with no observable effect. Each dose hits peak plasma levels within one to two hours and clears within four. At community doses of 50 to 200 mg per day, mitochondrial uncoupling probably stays below the threshold for measurable metabolic change. No accumulation happens between doses with a 1.7-hour half-life. Most users report nothing perceptible. Some describe mild warmth or slight sweating during the active dosing window. No body composition changes show up in week one. GI discomfort is possible if you skip the food; headache sometimes shows up during early dosing.

Weeks 2 through 4: Possible early metabolic signal. Mouse models at therapeutic dietary doses (0.10%) showed detectable insulin sensitivity improvements by weeks three and four. Whether sub-allometric human community doses produce any measurable metabolic shift is unverified. Anecdotal reports mention slightly more sweating during exercise and a mild reduction in appetite. No biomarker-confirmed human outcomes exist. GI effects fade for most people if dosing stays consistent.

Weeks 5 through 8: This is the window where mouse data gets interesting. Alexopoulos's group confirmed fat mass reduction and whole-body insulin sensitization after five weeks of 0.10% dietary dosing in C57BL/6J mice [1]. Hepatic lipid levels dropped. Body temperature stayed normal. Lean mass was preserved. On the human side, no structured outcome reports with biomarker confirmation exist. Individual anecdotes describe one to three kilograms of fat loss over eight weeks, but without controls, imaging, or bloodwork to confirm the mechanism.

Post-cycle (off weeks): Given the 1.7-hour half-life, pharmacological activity stops within four to eight hours of the last dose. No pharmacokinetic basis exists for a long washout period. Any fat loss you keep depends on diet. Users describe effects as reversible within days of stopping. No persistent metabolic adaptation has been reported.

Detailed Timeline: Science vs Community

Days 1–7
Science

Plasma exposure occurs within 1–2 hours of each dose but clears within 4 hours. At community doses (50–200 mg/day), mitochondrial uncoupling is likely sub-threshold for measurable metabolic effect. No accumulation between doses at 1.7-hour half-life.

Community

Most users report nothing perceptible. Some describe a very mild increase in warmth or sweat during dosing window. No body composition changes detectable in week 1.

Weeks 2–4
Science

In mouse models at therapeutic dietary doses (0.10%), insulin sensitivity improvements were detectable by week 3–4. At sub-allometric human community doses, any metabolic effect is unverified.

Community

Anecdotal reports of slightly increased sweat during workouts and minor reduction in appetite. No biomarker-confirmed outcomes available.

Weeks 5–8
Science

In Alexopoulos 2020, significant fat mass reduction and confirmed whole-body insulin sensitization were established after 5 weeks of 0.10% dietary dosing in mice (equivalent to ~500 mg/day allometrically). Hepatic lipid accumulation decreased. No body temperature change. Lean mass preserved.

Community

No structured human outcome reports with biomarker confirmation. Individual anecdotes describe 1–3 kg fat loss over 8 weeks but without controls or imaging to confirm.

Post-cycle (off weeks)
Science

Given 1.7-hour half-life, pharmacological effects cease within 4–8 hours of last dose. No pharmacokinetic basis for extended washout period. Any fat loss maintenance would depend on dietary adherence.

Community

Effects described as reversible within days of cessation. No persistent metabolic adaptation reported.

Pharmacokinetics

Half-Life
1.7h
Bioavailability
Oral: ~67% (mouse data)
Tmax
~1 hour (mouse data)
Data Confidence
low

Source: Alexopoulos et al. Nature Communications 2020 (PMID: 32409697): oral PK in C57BL/6J mice

Pharmacokinetics: Active Dose Over Time

t½ = ~1.7 hours

Disclaimer: This curve is a simplified first-order exponential decay model. Actual pharmacokinetics vary based on injection site, individual metabolism, body composition, and other factors. Half-life values are approximate and based on available preclinical and clinical literature. Many research peptides lack formal human pharmacokinetic studies. This is for educational purposes only, not medical advice.

Who Should Consider BAM-15

  • Researchers studying mitochondrial uncoupling and metabolic disease
  • Individuals interested in non-stimulant approaches to fat loss
  • People exploring alternatives to classical uncouplers like DNP
  • Those investigating adjuncts to diet and exercise for body composition
  • Metabolic optimization enthusiasts seeking preclinical-stage compounds

Related Peptides

What Changed for BAM-15

No material change since Oct 5, 2026. Checked against Federal Register, openFDA Drugs@FDA, openFDA drug labels, openFDA enforcement reports and PubMed retraction links on Oct 14, 2026. How the change record works

Peptide Schedule Research TeamReviewed Apr 7, 20269 Citations

References

  1. [1]Mitochondrial uncoupler BAM15 reverses diet-induced obesity and insulin resistance in mice (Nature Communications 2020) (opens in a new tab)PubMed (opens in a new tab)PubMed
  2. [2]Identification of a novel mitochondrial uncoupler that does not depolarize the plasma membrane (Mol Metab 2014) (opens in a new tab)PubMed (opens in a new tab)PubMed
  3. [3]Protonophoric action of BAM15 on planar bilayers, liposomes, mitochondria, bacteria and neurons (Bioelectrochemistry 2021) (opens in a new tab)PubMed (opens in a new tab)PubMed

Related Tools

Storage & Stability

Before Reconstitution
Store powder form at -20°C, desiccated, protected from light and moisture
After Reconstitution
Prepared solutions in DMSO stable at -20°C for up to 6 months; avoid repeated freeze-thaw cycles
Temperature
-20°C for long-term storage; room temperature stability is limited

Frequently Asked Questions

Not at all. Mouse data doesn't translate automatically to human safety. Long-term human toxicology, metabolic effects at gram-scale doses, and cardiovascular safety in metabolically compromised individuals have never been studied. The absence of hyperthermia in mice is mechanistically encouraging, not a human safety guarantee.

Capsule sizing reflects commercial convenience and research-chemical positioning, not a validated clinical dose. The gram-scale estimate comes from allometric scaling of mouse diet studies. The 15–50 mg capsule size is not a medically validated human protocol.

In mice, plasma levels drop substantially within 4 hours. For sustained effect in humans, split dosing (2–3 times daily) would be required to maintain therapeutic plasma concentrations. Single daily dosing almost certainly produces only transient metabolic effects given the rapid clearance.

No. BAM-15 is not a sympathomimetic. It doesn't raise catecholamines, stimulate the CNS, or raise heart rate. It dissipates the mitochondrial proton gradient, causing cells to burn fuel at the mitochondrial level. Body temperature did not increase even at supratherapeutic mouse doses. Don't expect the stimulant feel of ephedrine or clenbuterol.

BAM-15 has a mechanistically superior preclinical safety profile; mitochondrially selective, no hyperthermia at any tested mouse dose, and no plasma membrane depolarization. However, "research chemical" means no human safety data, no dosing standards, no quality control guarantee, and; as of 2026. WADA prohibition. The absence of documented human harm partly reflects how few people have used it, not an established safety record.